US › Healthcare

Pelthos Therapeutics Inc. (PTHS)

US · Healthcare · Biotechnology

$20.15-0.54%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$15.6M

Net profit

$-23.4M

EPS

$-6.62

EPS estimate

$-3.02

Net margin

-150.1%

EPS came in at -6.62 against a street estimate of -3.02 — a miss of 119.2%.

Key statistics

Market cap

$77.7M

Forward P/E

0.0

P/B

2.86

Book value

$-0.40

EPS (TTM)

$-27.53

52-week high

$37.50

52-week low

$18.19

50-day MA

$24.14

200-day MA

$24.85

Beta

3.11

Analyst view

with an average price target of $51.71.

Shareholding

Insiders

50.05%

Institutions

42.26%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Pelthos Therapeutics Inc. — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.